Profile data is unavailable for this security.
About the company
QuiaPEG Pharmaceuticals Holding AB is a Sweden-based biotechnology company. The Company develops improved versions of clinically validated biopharmaceutical drugs based on PEGylation technology platform. The Company’s technology is applicable on proteins, peptides and small molecules and offers a half-life extension platform consisting of covalent, as well as extended release PEGylation. The Company focuses on development of long-acting biopharmaceuticals for the treatment of metabolic disorders. The main project intends to reduce the frequent injection therapy by requiring significantly fewer injections. The Company offers out-licensing and partnering opportunities. It has a patent portfolio with patents pending and an approved the United States patent covering chemical linkers.
- Revenue in SEK (TTM)2.36m
- Net income in SEK-13.86m
- Incorporated2004
- Employees8.00
- LocationQUIA PHARMA AB (publ)Uppsala Business ParkVirdings Alle 32 BUPPSALA 754 50SwedenSWE
- Phone+46 87780006
- Fax+46 87780005
- Websitehttps://www.quiapeg.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cyxone AB | 0.00 | -22.16m | 12.56m | 3.00 | -- | 0.2684 | -- | -- | -0.1388 | -0.1388 | 0.00 | 0.1248 | 0.00 | -- | -- | 0.00 | -59.57 | -63.71 | -66.38 | -69.40 | -- | -- | -- | -- | -- | -- | 0.0157 | -- | -- | -- | 45.87 | -- | -13.31 | -- |
| XP Chemistries AB | 393.54k | -7.43m | 17.89m | 2.00 | -- | 0.5219 | -- | 45.46 | -0.2059 | -0.2059 | 0.0066 | 0.2357 | 0.0159 | 3.01 | 3.45 | 196,770.00 | -29.91 | -- | -31.74 | -- | -1,218.83 | -- | -1,887.54 | -- | 3.76 | -- | 0.00 | -- | -37.14 | -- | -1.55 | -- | -- | -- |
| Lipigon Pharmaceuticals AB | 9.33m | -20.25m | 24.03m | -- | -- | 0.9519 | -- | 2.58 | -0.3541 | -0.3541 | 0.1012 | 0.1702 | 0.2851 | -- | 0.7439 | -- | -61.91 | -314.67 | -76.67 | -426.49 | -- | -- | -217.15 | -488.14 | -- | -- | 0.00 | -- | -- | 444.44 | 67.83 | -- | -- | -- |
| Ziccum AB | 5.56m | -23.18m | 37.82m | 10.00 | -- | 4.46 | -- | 6.81 | -1.63 | -1.63 | 0.3903 | 0.5312 | 0.2749 | -- | 3.31 | 694,500.00 | -114.67 | -68.51 | -163.12 | -76.47 | -- | -- | -417.19 | -2,598.03 | -- | -- | 0.0654 | -- | -- | 75.20 | 25.62 | -- | -13.45 | -- |
| StenoCare A/S | 4.90m | -26.36m | 40.90m | 9.00 | -- | 1.27 | -- | 8.34 | -1.04 | -1.04 | 0.1868 | 1.01 | 0.0948 | -- | 2.07 | -- | -50.98 | -28.16 | -68.69 | -35.47 | -- | -- | -537.63 | -371.06 | 0.6143 | -6.07 | 0.2763 | -- | -16.30 | -- | -7.77 | -- | -- | -- |
| QUIA PHARMA AB (publ) | 2.36m | -13.86m | 41.72m | 8.00 | -- | 1.20 | -- | 17.68 | -2.02 | -2.02 | 0.0119 | 0.0233 | 0.0703 | -- | 21.36 | -- | -41.30 | -95.67 | -50.35 | -207.86 | 160.51 | 262.59 | -587.29 | -5,002.50 | -- | -46.79 | 0.00 | -- | -- | -- | 17.75 | -- | 47.06 | -- |
| Odi Pharma AB (publ) | 22.45m | 355.97k | 48.10m | -- | 135.10 | 21.69 | 134.00 | 2.14 | 0.0234 | 0.0234 | 1.47 | 0.1457 | 2.19 | 54.42 | 5.47 | -- | 3.48 | -35.08 | 14.86 | -44.27 | 2.07 | -- | 1.59 | -99.25 | 1.22 | 1.81 | -- | -- | 15,995.75 | -- | 105.16 | -- | -- | -- |
| Arctic Bioscience AS | 30.69m | -47.25m | 51.55m | 20.00 | -- | 0.2245 | -- | 1.68 | -1.91 | -1.91 | 1.24 | 9.27 | 0.1057 | 0.674 | 2.25 | 1,570,792.00 | -16.27 | -- | -18.44 | -- | 29.20 | -- | -153.95 | -- | 1.21 | -- | 0.0075 | -- | -1.52 | -- | -33.77 | -- | -- | -- |
| ExpreS2ion Biotech Holding AB | 8.10m | -45.37m | 56.71m | 18.00 | -- | 0.629 | -- | 7.00 | -29.54 | -29.54 | 5.47 | 42.93 | 0.0772 | -- | 6.46 | 311,461.50 | -43.23 | -63.54 | -56.21 | -75.88 | -123.56 | -1.94 | -560.27 | -524.31 | -- | -- | 0.0065 | -- | 43.07 | -0.1561 | 22.94 | -- | 19.90 | -- |
| Elicera Therapeutics AB | 12.07m | -20.79m | 69.31m | 2.00 | -- | 2.68 | -- | 5.74 | -0.9137 | -0.9137 | 0.5059 | 0.7377 | 0.3224 | -- | 12.85 | 6,035,610.00 | -55.51 | -40.06 | -79.82 | -49.74 | -- | -- | -172.21 | -415.41 | -- | -- | 0.00 | -- | 777.23 | -- | 15.64 | -- | -- | -- |
| Oncozenge AB | 0.00 | -11.78m | 107.88m | -- | -- | 7.59 | -- | -- | -1.01 | -1.01 | 0.00 | 1.21 | 0.00 | -- | -- | -- | -55.08 | -- | -59.44 | -- | -- | -- | -- | -- | -- | -2,944.50 | 0.00 | -- | -- | -- | 65.91 | -- | -- | -- |
| Lipidor AB | 87.00k | -13.53m | 113.88m | -- | -- | 6.77 | -- | 1,308.93 | -0.1505 | -0.1505 | 0.0009 | 0.0207 | 0.005 | -- | 0.1843 | -- | -77.12 | -59.41 | -178.11 | -75.10 | -- | -- | -15,550.58 | -643.36 | -- | -- | 0.00 | -- | 73.33 | -20.33 | 72.24 | -- | -- | -- |
Data as of Nov 06 2024. Currency figures normalised to QUIA PHARMA AB (publ)'s reporting currency: Swedish Krona SEK
0.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FCG Fonder ABas of 30 Sep 2024 | 163.60k | 0.22% |
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
